sodium arsenite has been researched along with Glioblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, DH; Kim, YN; Koo, KH; Lee, CH; Lee, EJ; Park, J; Park, JB; Shim, J; Sung, JY | 1 |
| Ham, Y; Jin, J; Joo, KM; Kang, W; Kim, S; Nam, DH; Woo, SR; Yang, H | 1 |
2 other study(ies) available for sodium arsenite and Glioblastoma
| Article | Year |
|---|---|
Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenites; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sodium Compounds; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.
Topics: Animals; Apoptosis; Arsenites; Dacarbazine; DNA Damage; Drug Synergism; Glioblastoma; Humans; Mice; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Sodium Compounds; Telomere; Temozolomide; Xenograft Model Antitumor Assays | 2014 |